NR4A2
ENSG00000153234
Target class
Nuclear receptor
Chromosome
2
- ClinGen gene-disease validity
- Definitive
- Chemical probe available
- No
- Target name
- NR4A2
- Gene name
- Nuclear receptor subfamily 4 group A member 2
- Gene symbol
- NR4A2
- Previous gene symbols
- NURR1
- Protein name
- Nuclear receptor subfamily 4 group A member 2 (Immediate-early response protein NOT) (Orphan nuclear receptor NURR1) (Transcriptionally-inducible nuclear receptor)
- TINUR
- NOT
- RNR1
- HZF-3
- Gene biotype
- Protein coding
- Gene family
- Nuclear receptor subfamily 4 group A
- Target class
- Nuclear receptor
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 145.8
- Tissue specificity (Gini)
- 0.568
- Tissue specificity (tau)
- 0.9
- KEGG gene identifiers
- hsa:4929
- Protein interaction confidence
- 0.804412
- Protein interaction partners
- 17
- R-HSA-383280
- R-HSA-4090294
- End position
- 156342348
- Start position
- 156324432
- Chromosome
- 2
- Strand
- Reverse
- Cytoplasm . Nucleus . Note=Mostly nuclear
- oxidative stress promotes cytoplasmic localization. .
- Nuclear speckles
- PubMed 23283970
- PubMed 17184956
- Tissue specificity (tau)
- 0.89995
- Expression inequality (Gini)
- 0.567592
Expression in transcripts per million
- Ovary
- 145.8
- Nerve - Tibial
- 90.99
- Artery - Tibial
- 65.03
- Pituitary
- 49.38
- Adipose - Visceral (Omentum)
- 48.13
Expression in transcripts per million
- Ovary145.8
- Nerve - Tibial90.99
- Artery - Tibial65.03
- Pituitary49.38
- Adipose - Visceral (Omentum)48.13
- Fallopian Tube35.21
- Brain - Cerebellar Hemisphere32.98
- Artery - Aorta29.12
- Brain - Cerebellum28.54
- Artery - Coronary25.96
- Lung20.81
- Prostate19.07
- Breast - Mammary Tissue17.96
- Thyroid17.93
- Adipose - Subcutaneous17.54
- Cervix - Ectocervix14.26
- Stomach13.9
- Heart - Atrial Appendage13.78
- Skin - Not Sun Exposed (Suprapubic)13.49
- Cervix - Endocervix13.49
- Vagina13.22
- Skin - Sun Exposed (Lower leg)13
- Esophagus - Gastroesophageal Junction12.22
- Minor Salivary Gland11.61
- Adrenal Gland11.35
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0001764
- GO:0006351
- GO:0045944
- GO:0060070
- GO:1904948
- GO:2001234
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0016607
- GO:0032991
- GO:0003677
- GO:0004879
- GO:0005515
- GO:0008013
- GO:0046965
- GO:1990837
regulation of transcription factor activity
Studies
- cell-based: ATG_NURR1_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
Biological samples
- HepG2, cell line
Evidence source
Related records
Trials (10)
- A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
- IMU-838 and Oseltamivir in the Treatment of COVID-19
- MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
- Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
- SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease
- SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
- Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
- Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
- Vidofludimus Calcium for Primary Sclerosing Cholangitis